Study
Beyond's analysis on Study
- — Astellas initiates Phase 3 trial of ASP2138 for CLDN18.2-positive gastric cancer, advancing its oncology pipeline
- — Hofseth BioCare’s peer‑reviewed ProGo study demonstrates GLP‑1‑like effects and increased lean muscle mass, strengthening its position in the functional protein market
- — The Alzheimer's Association launches a global trial testing whether combining a proven lifestyle program with a GLP‑1 drug can slow cognitive decline, potentially reshaping prevention strategies and market dynamics for neurodegeneration therapies
Recent news mentioning Study
- — Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System
- — Isomab presents landmark data study supporting safety of angiogenic approaches in coronary artery disease
- — Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
- — Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
- — 2026 Corporate AI Talent Study Report Available
- — Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
- — Air pollution from ships may be more harmful than road traffic emissions, port study finds
- — New study: Professionals say AI is already reshaping research hiring, and early-career roles are the most exposed
- — Rich people more likely to steal children’s sweets, finds Ig Nobel prize-winning study
- — Australian science prize awarded to researcher studying memory accuracy of domestic violence survivors
- — Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint
- — Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026